William B. Stilley
Chief Executive Officer and President
William B. Stilley
Chief Executive Officer and President
William B. Stilley has served as our Chief Executive Officer since December 2010. Prior to joining Adial Pharmaceuticals, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (NASDQ CLDA), where he worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the Company’s vasodilator drug for myocardial stress imaging.Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps.
Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. Until recently, he guest lectured at the Darden School of Business in two courses on the management of life science companies. He currently serves on the Board of Virginia BIO, the statewide biotechnology organization. He also holds a patent for Stedivaze®, which is currently in Phase 3 clinical development.
Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI
Founder and Chief Medical Officer
Dr. Bankole Johnson has been our Chief Medical Officer since March 24, 2019, after having served as the Chairman of our Board since November 2010. Dr. Johnson is a world-leading neuroscientist and a pioneer in the development of medications for the treatment of alcohol abuse and is the inventor of all patents covering AD04. Prior to accepting his appointment as our Chief Medical Officer, he was Chair of the Department of Psychiatry at the University of Maryland School of Medicine and led the Brain Science Research Consortium Unit at the University of Maryland. Previously, from 2004 until August 2013, he served as Alumni Dr. and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia.
Dr. Johnson graduated in Medicine from Glasgow University in 1982 and trained in Psychiatry at the Royal London and Maudsley and Bethlem Royal Hospitals. Additional to his medical degree, he trained in research at the Institute of Psychiatry (University of London) and conducted studies in neuropsychopharmacology for his doctoral thesis (degree from Glasgow University) on the Medical Research Council unit at Oxford University. More recently, in 2004, Dr. Johnson earned his Doctor of Science degree in Medicine from Glasgow University—the highest degree that can be granted in science by a British university. His primary area of research expertise is the neuropsychopharmacology of medications for treating addictions.
Dr. Johnson is a licensed physician and board-certified psychiatrist throughout Europe and in the U.S. He is the Principal Investigator on National Institutes of Health (NIH)-funded research studies utilizing neuroimaging, neuropharmacology, and molecular genetics techniques. Dr. Johnson’s clinical expertise is in the fields of addiction, biological, and forensic psychiatry. Honors include service on numerous NIH review and other committees including special panels.
Dr. Johnson was the 2001 recipient of the Dan Anderson Research Award for his “distinguished contribution as a researcher who has advanced the scientific knowledge of addiction recovery.” He received the Distinguished Senior Scholar of Distinction Award in 2002 from the National Medical Association. Dr. Johnson also was an inductee of the Texas Hall of Fame in 2003 for contributions to science, mathematics, and technology, and in 2006 he received the American Psychiatric Association’s (APA’s) Distinguished Psychiatrist Lecturer Award. In 2007, he was named as a Fellow in the Royal College of Psychiatrists, and in 2008 he was elected to the status of Distinguished Fellow of the APA. In 2009, he received the APA’s Solomon Carter Fuller Award, honoring an individual who has pioneered in an area that has benefited significantly the quality of life for Black people. In 2010, he was named as a Fellow in the American College of Neuropsychopharmacology. In 2013, Dr. Johnson was honored by the NIH as a recipient of the Jack Mendelson Award for work that has “transformed our understanding of how abnormalities of the brain promote addiction”. And, in 2019, he is the recipient of the R. Brinkley Smithers Distinguished Scientist Award from the American Society for Addiction Medicine, which “recognizes and honors an individual who has made highly meritorious contributions in advancing the scientific understanding of alcoholism an, its prevention and treatment”
Dr. Johnson was Field Editor-in-Chief of Frontiers in Psychiatry, serves on the Editorial Board of The American Journal of Psychiatry, and reviews for over 30 journals in pharmacology, neuroscience, and the addictions. He has over 200 publications and 15,459 citations (h-index = 56; see http://en.wikipedia.org/wiki/H-index). Dr. Johnson also has edited three books: Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior, Handbook of Clinical Alcoholism Treatment, and Addiction Medicine: Science and Practice, one of the foremost reference textbooks in the field. The second edition of Addiction Medicine: Science and Practice is scheduled to be released in 2019.
Dr. Johnson has served as a consultant to Johnson & Johnson (Ortho-McNeil Janssen Scientific Affairs, LLC), Transcept Pharmaceuticals, Inc., D&A Pharma, Organon, Psychological Education Publishing Company (PEPCo LLC), and Eli Lilly and Company. He also has served on the Extramural Advisory Board for the National Institute of Alcoholism and Alcohol Abuse (NIAAA) (2004-present), the National Advisory Council for the National Institute of Drug Addictions (NIDA) (2004-2007), the Medications Development Subcommittee of NIDA’s Advisory Council on Drug Abuse (2004-2007), and the Medications Development Scientific Advisory Board for NIDA (2005-2009). In addition, he has been the recipient of research grant support from both NIAAA and NIDA.
Dr. Johnson’s curriculum vitaecan be viewed by clicking here
Chief Operating Officer & Chief Financial Officer
Joseph Truluck was appointed as our Chief Operating Officer and CFO in 2017 and, since May 2016, has been our VP Operations and Finance. Since January 2013, Mr. Truluck has served as the VP Operations and Finance at Adenosine Therapeutics, after the company reacquired its major drug development program. As VP, Operations & Finance, at Adenosine Therapeutics, Mr. Truluck has overseen the operations of the business, including seeing to completion a project to merge and analyze two partially completed Phase 3 trials to constitute a single trial. Previously, Mr. Truluck served as the Operations Manager of Adenosine Therapeutics’ until its purchase by Clinical Data (NASDAQ:CLDA). He is the co-founder and former VP Operations and Finance for Beonten, Inc., a software development company. Beonten’s goal was the creation of a software platform for knowledge management and sharing. Beonten was a Semi-Finalist in the prestigious MIT 100K business plan competition. Mr. Truluck has a MBA from Tulane University with a concentration in Finance and an MA in Philosophy at the University of Virginia, with a thesis in the area of modal semantics.
Monika Z. Rogozinska
Chief Development Officer
Monika Rogozinska joined the Company in August 2018. Before joining Adial, Ms. Rogozinska served as Vice President and Head of Portfolio, Program & Project Management at ECRC in Boston, where she managed a portfolio of complex projects as the clinical contact and spokesperson for potential licensing, acquisition, collaborations, co-development agreements, and strategic alliances. Previously, Ms. Rogozinska held the position of Senior Director and Global Program Leader at EMD Serono, an affiliate of Merck KGaA, where she led the clinical development, regulatory submissions and lifecycle management of various drugs under clinical development including Bavencio® (avelumab). In collaboration with Pfizer, she was accountable for the clinical development and operational plans leading to a total of 30 ongoing clinical programs, 9 pivotal studies and 2,200 patients treated. Ms. Rogozinska’s program enabled the accelerated FDA approval and commercial product launch of Bavencio® in just 4 years. Ms. Rogozinska also held senior clinical and operational roles with Pfizer, Covidien, and Quintiles. While at EDM Serono, she received the Merck KGaA CEO 2015 Award. Ms. Rogozinska graduated from the General Management Program at Harvard Business School and holds a Master of Science in Pharmacy degree from Nicolaus Copernicus University.
Chief Business Officer